Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

New therapeutic options in advanced and metastatic breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 19.10.18
Views: 1261

Dr Fatima Cardoso - Champalimaud Clinical Center, Lisbon, Portugal

Dr Fatima Cardoso talks to ecancer at the ESMO 2018 congress in Munich about the latest in breast cancer research reported at the conference.

She highlights the results from SOLAR-1, IMpassion130, and PALOMA-3 as important, and reflects on the need for trial designs with overall survival as a co-endpoint from the outset.

Dr Cardoso also discusses the impact of CDK inhibitors on breast cancer care, and how research in disease progression after CDK therapy is required.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

ONJ e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation